Search Results - "Strout, Patrick"

Hydrolytically Stable Site-Specific Conjugation at the N‑Terminus of an Engineered Antibody by Thompson, Pamela, Bezabeh, Binyam, Fleming, Ryan, Pruitt, Monica, Mao, Shenlan, Strout, Patrick, Chen, Cui, Cho, Song, Zhong, Haihong, Wu, Herren, Gao, Changshou, Dimasi, Nazzareno

“…Antibody–drug conjugates (ADCs) have emerged as an important class of therapeutics for cancer treatment that combine the target specificity of antibodies with…”
Get full text

Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies by Rios-Doria, Jonathan, Harper, Jay, Rothstein, Raymond, Wetzel, Leslie, Chesebrough, Jon, Marrero, Allison, Chen, Cui, Strout, Patrick, Mulgrew, Kathy, McGlinchey, Kelly, Fleming, Ryan, Bezabeh, Binyam, Meekin, John, Stewart, David, Kennedy, Maureen, Martin, Philip, Buchanan, Andrew, Dimasi, Nazzareno, Michelotti, Emil, Hollingsworth, Robert

“…Immunogenic cell death (ICD) is the process by which certain cytotoxic drugs induce apoptosis of tumor cells in a manner that stimulates the immune system. In…”
Get full text

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics by Thompson, Pamela, Fleming, Ryan, Bezabeh, Binyam, Huang, Fengying, Mao, Shenlan, Chen, Cui, Harper, Jay, Zhong, Haihong, Gao, Xizhe, Yu, Xiang-Qing, Hinrichs, Mary Jane, Reed, Molly, Kamal, Adeela, Strout, Patrick, Cho, Song, Woods, Rob, Hollingsworth, Robert E., Dixit, Rakesh, Wu, Herren, Gao, Changshou, Dimasi, Nazzareno

“…Antibody-drug conjugates (ADCs) are among the most promising empowered biologics for cancer treatment. ADCs are commonly prepared by chemical conjugation of…”
Get full text

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer by Cho, Song, Zammarchi, Francesca, Williams, David G, Havenith, Carin E G, Monks, Noel R, Tyrer, Peter, D'Hooge, Francois, Fleming, Ryan, Vashisht, Kapil, Dimasi, Nazzareno, Bertelli, Francois, Corbett, Simon, Adams, Lauren, Reinert, Halla W, Dissanayake, Sandamali, Britten, Charles E, King, Wanda, Dacosta, Karma, Tammali, Ravinder, Schifferli, Kevin, Strout, Patrick, Korade, 3rd, Martin, Masson Hinrichs, Mary Jane, Chivers, Simon, Corey, Eva, Liu, He, Kim, Sae, Bander, Neil H, Howard, Philip W, Hartley, John A, Coats, Steve, Tice, David A, Herbst, Ronald, van Berkel, Patrick H

“…Prostate-specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase that is highly expressed in nearly all prostate cancers with the…”
Get full text

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4 by Harper, Jay, Lloyd, Christopher, Dimasi, Nazzareno, Toader, Dorin, Marwood, Rose, Lewis, Leeanne, Bannister, David, Jovanovic, Jelena, Fleming, Ryan, D'Hooge, Francois, Mao, Shenlan, Marrero, Allison M, Korade, 3rd, Martin, Strout, Patrick, Xu, Linda, Chen, Cui, Wetzel, Leslie, Breen, Shannon, van Vlerken-Ysla, Lilian, Jalla, Sanjoo, Rebelatto, Marlon, Zhong, Haihong, Hurt, Elaine M, Hinrichs, Mary Jane, Huang, Keven, Howard, Philip W, Tice, David A, Hollingsworth, Robert E, Herbst, Ronald, Kamal, Adeela

“…Antibody-drug conjugates (ADC) are used to selectively deliver cytotoxic agents to tumors and have the potential for increased clinical benefit to cancer…”
Get full text

Evaluation of anti-cancer stem cell activity of the anti-DLL4 antibody MEDI0639 in a phase I clinical trial of SCLC by Bao, Haifeng, Chen, Xiaoru, Thomas, Suneetha, Shi, Xiaoqing, Strout, Patrick, Hurt, Elaine, Cho, Song, Burke, Patricia A, Dar, Mohammed M.

“…Abstract only…”
Get full text

Abstract 4596: Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads alter the tumor immune microenvironment and synergize with multiple immunotherapies by Rios-Doria, Jonathan, Harper, Jay, Rothstein, Raymond, Wetzel, Leslie, Chesebrough, Jon, Marrero, Allison, Chen, Cui, Strout, Patrick, Mulgrew, Kathy, McGlinchey, Kelly, Fleming, Ryan, Bezabeh, Binyam, Meekin, John, Stewart, David, Kennedy, Maureen, Martin, Philip, Buchanan, Andrew, Dimasi, Nazzareno, Michelotti, Emil, Hollingsworth, Robert

“…Abstract Immunogenic cell death (ICD) is the process by which certain cytotoxic drugs induce apoptosis of tumor cells in a manner that stimulates the immune…”
Get full text

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer by White, Jason B, Fleming, Ryan, Masterson, Luke, Ruddle, Ben T, Zhong, Haihong, Fazenbaker, Christine, Strout, Patrick, Rosenthal, Kim, Reed, Molly, Muniz-Medina, Vanessa, Howard, Philip, Dixit, Rakesh, Wu, Herren, Hinrichs, Mary Jane, Gao, Changshou, Dimasi, Nazzareno

“…Most strategies used to prepare homogeneous site-specific antibody-drug conjugates (ADCs) result in ADCs with a drug-to-antibody ratio (DAR) of two. Here, we…”
Get full text

Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models by Cho, Song, Zammarchi, Francesca, Monks, Noel R., Vashisht, Kapil, Tammali, Ravinder, Schifferli, Kevin, Strout, Patrick, King, Wanda, Dacosta, Karma, Fleming, Ryan, Williams, David G., Havenith, Karin, Hinrichs, Mary Jane Masson, Chivers, Simon, Dimasi, Nazzareno, Howard, Phil W., Hartley, John A., Coats, Steve, Herbst, Ronald, Berkel, Patrick H. van, Tice, David A.

“…Abstract Prostate specific membrane antigen (PSMA), a type II membrane glycoprotein, is highly expressed in nearly all prostate cancers, with the highest…”
Get full text

Generation of a functional humanized Delta-like ligand 4 transgenic mouse model by Wiseman, John, Gregersson, Pernilla, Johansson, Johan, Magnell, Kerstin, Pilataxi, Fernanda, Morehouse, Chris, Brohawn, Philip, Holoweckyj, Nicholas, Strout, Patrick, Cho, Song

“…Humanized mouse models are important tools in many areas of biological drug development including, within oncology research, the development of antagonistic…”
Get full text

Abstract A49: Anti-DLL4 antibodies inhibit cancer stem cells in small cell lung cancer by Strout, Patrick, Korade, Martin, Leow, Ching Ching, Inigo, Ivan, Thomas, Suneetha, Hurt, Elaine, Chesebrough, Jon, Kamal, Adeela, Cho, Song

“…Abstract Small cell lung cancer (SCLC) is a very aggressive lung cancer with features suggesting enrichment in cancer stem cells (CSCs). Delta-like ligand 4…”
Get full text

Abstract 5098: A mouse DLL4 cross-reactive variant of MEDI0639 disrupts functional vessel formation and inhibits tumor growth in preclinical models by Cho, Song H., Jenkins, David W., Strout, Patrick, Korade, Martin, Zhong, Haihong, Leow, Ching Ching, Breen, Shannon, Chesebrough, Jon, Holoweckyj, Nicholas, Inigo, Ivan, Gololobov, Gennady, Tsui, Ping, Cook, Kimberly, Damschroder, Melissa, Czapiga, Meggan, Brohawn, Philip, Huang, Jiaqi, Ricketts, Sally-Ann, Maynard, Juliana, Kamal, Adeela

“…Abstract Delta-like ligand 4 (DLL4) is a membrane bound ligand for Notch receptors essential for functional vessel formation during development and…”
Get full text

Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization by Harper, Jay, Mao, Shenlan, Strout, Patrick, Kamal, Adeela

“…Antibody-drug conjugates (ADCs) combine the selectivity of a monoclonal antibody with the killing potency of a cytotoxic drug. For an antibody to function as a…”
Get more information

Abstract B233: c-Met antagonist Avimer™ polypeptide that exhibits potent in vivo and in vitro inhibitor activity by Cho, Song, Smith, Richard, Duguay, Amy, Li, Peng, Bakker, Alice, Alba, Ben, Thomas, Melissa, To, Wayne, Silverman, Josh, Swimmer, Candace, Moore, Kevin, Strout, Patrick, Bobofchak, Kevin, McCarthy, Mike, Pemmaraju, Kalyani, Lacourciere, Gerard, Zhou, Qin, Damschroder, Melissa, Wu, Herren, Coats, Steve, Kamal, Adeela

“…Abstract c-Met is a receptor tyrosine kinase (RTK) that is activated upon binding to its only known ligand, hepatocyte growth factor (HGF). Although essential…”
Get full text

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer by White, Jason B., Fleming, Ryan, Masterson, Luke, Ruddle, Ben T., Zhong, Haihong, Fazenbaker, Christine, Strout, Patrick, Rosenthal, Kim, Reed, Molly, Muniz-Medina, Vanessa, Howard, Philip, Dixit, Rakesh, Wu, Herren, Hinrichs, Mary Jane, Gao, Changshou, Dimasi, Nazzareno

“…Most strategies used to prepare homogeneous site-specific antibody-drug conjugates (ADCs) result in ADCs with a drug-to-antibody ratio (DAR) of two. Here, we…”
Get full text